Ziritaxestat, also known as GLPG1690, is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement.
武漢永璨生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
武漢永璨生物